• Peptide tyrosine-tyrosine (PYY) and neuropeptide tyrosine (NPY) 
INTRODUCTION
• PYY and NPY were originally extracted and purified from porcine small intestine and brain, respectively (1) (2) (3) (4) (5) . Both contain 36 amino acids, show a 70% sequence homology and display a high degree of three dimensional structural conservation (3, 5) . PYY-releasing endocrine cells are located mainly in the mucosa of the terminal ileum and colon (4- 
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In contrast, NPY is one of the most abundant peptides found in neurons in the brain. It is concentrated in neural pathways associated with the control of feeding behaviour, endocrine and autonomic functions. Its synthesis and release are strongly associated with physiological conditions leading to increased food intake such as growth, pregnancy, and starvation. NPY injections into hypothalamic and brainstem structures associated with the control of feeding behaviour elicit dramatic 8 elevations in feeding (11) (12) (13) (14) (15) .
PYY EFFECTS ON DIGESTIVE PROCESSES
• Following a meal, PYY levels in plasma are increased significantly and remain elevated for several hours (4, 5) . Circulating PYY concentrations can also be specifically elevated in response to direct infusion of oleate into the ileum (5, 6, 10) . PYY produces inhibitory effects on digestive functions, gastric acid output, motility, and emptying as well as reduction of stimulated pancreatic exocrine secretion, and a prolongation of intestinal transit time (4, 5, 7, 8, (16) (17) (18) . All of these effects are dependent upon intact vagal connections between the brainstem and the digestive tract (5) .
DORSAL VAGAL COMPLEX: CENTRAL NERVOUS SYSTEM TARGET FOR THE HORMONAL ACTION OF PYY
• The dorsal vagal complex of the medulla oblongata (DVC) contains the basic neuronal circuitry for the reflex vagal control of digestion, often termed the vago-vagal reflexes. Vago-vagal reflex control is mediated by general visceral afferent fibers in the vagus nerve which carry a wide variety of sensory information from the gut. These vagal afferent fibers synapse in the nucleus of the solitary tract (NST). This nucleus maintains connections with vagal motorneurons in the dorsal motor nucleus of the vagus (DMN), which are the source of virtually all parasympathetic innerva-tion of the subdiaphragmatic viscera (19) . The NST is also the source of input to interneurons in the reticular formation which control, by descending pathways, sympathetic efferent activity in preganglionic neurons of the intermediolateral cell column (20) . Additionally, the NST is the principal source of ascending visceral afferent information used by other central nervous system (CNS) structures to monitor a wide variety of physiological parameters including, but certainly not limited to, the progress of digestion of a meal.
Several categories of vago-vagal reflexes have been identified. The simplest such reflex is the gastric accommodation reflex, which utilizes mucosal contact receptors in the antrum to control the parasympathetic "tone" of the proximal stomach, and the rate of delivery of chyme to the duodenum. Evidence suggests that this is a simple disynaptic reflex whereby activation of vagal afferents activates NST neurons which, in turn, inhibit excitatory cholinergic neurons in the DMN (21, 22) . Other vago-vagal reflex "types" may be much more complicated. The gastric receptive relaxation reflex which is elicited by the activation of esophageal distension sensors during swallowing serves as an example. This reflex may involve the simultaneous and coordinated inhibition of DMN neurons controlling cholinergic excitation of the stomach and excitation of DMN neurons controlling the inhibitory non-adrenergic, non-cholinergic (NANC) enteric inputs to gastric smooth muscle (23) . The -end result is the relaxation of the proximal stomach to accept ingesta.
Evidence has accumulated over the last few years which suggests that this brainstem region, which contains the digestive tract reflex control circuits, i.e. the DVC, may be outside the confines of the "blood-brain barrier" (24) (25) (26) . Therefore, vagovagal reflex circuitry in the brainstem may also be under "humoral afferent control" (20) . The best example for such "endoneurocrine" regulation of autonomic functions may be found in the explanation of the gastroinhibitory effects of PYY.
Saturable and specific binding of circulating PYY to sites in the DVC has been demonstrated (26) . This suggests that circulating PYY is capable of exerting direct feedback control ove* th/e progress of digestion by actmg OTI vago-vagal reflex, control circuitry. Our earlier physiological studies showed that microinjection of low doses (4-400 fmol in 20 nL) of PYY into the DVC could produce a vagally-mediated suppression of stimulated gastric motility (27) . On the basis of this evidence, we suggested that PYY could be responsible for an "ileal brake" effect on gastric motility. In other words, ileal filling induces a negative feedback suppression of further gastric transit via PYY release. Circulating PYY then acts directly on vagal regulatory circuits in the brainstem to control gastric function (20) . However, relatively higher doses of PYY (greater than 4 pmol in 20 nL) applied to the same brainstem area, i.e. the DVC, can also strongly activate gastric functions (27, 28) . This dichotomy of CNS effects is also elicited by NPY. Thus, many reports link the release of NPY with the augmentation of motility (and other gastrointestinal functions) during the "cephalic phase" of digestion associated with food intake (29) (30) (31) (32) . Others, however, find that NPY injected centrally reduces digestive functions possibly via action on the same circuitry (33) (34) (35) . One explanation for the apparent paradoxical experimental effects of NPY and PYY may have to do with the existence of multiple receptor populations for these peptides which overlap in the DVC.
Binding sites for both PYY and NPY have been identified in the peripheral tissues and in the CNS. For example, PYY receptors have been found along the gastrointestinal tract as well as pancreas, spleen, kidney tubules, and several neuroendocrine cell lines (1, (36) (37) (38) (39) (40) (41) . In the brain, NPY and PYY binding sites are seen in a variety of areas, including cortex, hypothalamus, pons and, especially, the medulla oblongata (11, 15, 23) . Results from binding studies have characterized at least five distinct subtypes of receptors for NPY and PYY, denoted Yl through Y5. Two of these receptors subtypes, Yl and Y2, are both found in large quantities in the dorsal vagal complex of the medulla. Both Y1 and Y2 receptors bind PYY
Rogers and Hermann

56
Peptide YY, neuropeptide Y, and control of digestion and NPY with high affinity (42) . The Y2 subtype can be activated by C-terminal fragments of PYY and NPY, while the Yl subtype requires a full sequence of either polypeptide (13, 42) . The DVC area containing Yl and Y2 receptors receives an especially dense NPYergic terminal innervation (11, 43) . Additionally, a specific receptor for the structurally similar pancreatic polypeptide (PP) has been described (13, 15, (44) (45) (46) (47) . Therefore, the overlapping distribution of Yl and Y2 receptors in the DVC may explain some of the confusion concerning the physiological role of PYY and NPY to modulate vago-vagal reflex control of gastric motility. To test this idea, we investigated the effects of PYY, NPY, Yl, and Y2 agonists on gastric motility (measured by strain gauges) when microinjected directly into the DVC under conditions of either maximal central vagal stimulation of motility or in the basal, unstimulated state (12, 48, 49) .
DVC ACTIONS OF PYY, NPY AND ANALOGS
• PYY is normally released following feeding behaviour when gastrointestinal motility is elevated (4-6,10). To model this motility state in the anesthetized rat, the peptide thyrotro-pin releasing hormone (TRH) is microinjected onto the DVC. This peptide, which is normally released from terminal endings of the raphe nuclei in the brainstem onto neurons of the DMN, promotes a specific excitation of parasympathetic vagal projections to the stomach thus mimicking the increase in gastric motility following feeding (20, (50) (51) (52) .
Microinjection of the Y2 agonist (PYY 13-36) into the DVC (20 nL containing graded concentrations of the agonist peptides) causes a dose-dependent inhibition of TRH-stimulated antral motility as previously seen (27) after microinjection of the full sequence of PYY (Fig. 1 tions of the Yl agonist (LeuSl, Pro34 NPY) produced no apparent reduction in the TRH-stimulated increase of antral motility. Although application of the full sequence of NPY to the DVC inhibited motility more than Yl agonist, the inhibition was not as potent as that produced by equal doses of PYY or Y2 agonist injections into the DVC. Figure 2 illustrates the Rogers and Hermann 58 Peptide YY, neuropeptide Y, and control of digestion typical effects of all four peptides on strain-gauge recordings of gastric motility (48) .
The results on motility are exactly reversed for the effects of NPY, Yl and Y2 analogs in the DVC on basal gastric motility: the Yl agonist and NPY strongly activated motility from the low, basal state, while the Y2 agonist produced no effect on the already low motility. Figure 3 shows the typical effects of these peptides on gastric motility when applied to the DVC under anesthesia. Obviously, the anesthetic state of the preparation may significantly alter the motility level of the rat, as well as bias the effects of centrally applied peptides. However, it has been observed recently that the intracisternal application of PYY in awake rats produces a dose-dependent inhibition of gastric motility which is vagally-mediated (Fig. 4) (49).
• Neurophysiological Studies
The effects of Yl and Y2 agonists on the excitability of vagal efferent neurons in the DMN show that these neurons may be an important target of the direct effects of PYY and NPY. 
Intracisternal PYY in the awake rat suppresses gastric transit; the effect is mediated by the vagus nerve. Effects on gastric transit of intracisternal injections of vehicle (PBS), 400fmol of PYY in PBS or the TRH agonist RX77368 (33 pmol). Vagotomy does not effect basal, i.e. vehicle injection, gastric emptying in this model, but does eliminate the inhibitory effects of PYY as well as the excitatory effects of the TRH analog known to act via vagal efferents (REF). Numbers on graph indicate Nfor each experimental group. ** = P<0.01, Dunnetts test. From Ref 49.
PYY, Y2 AGONISTS AND GASTROINHIBITION; THE JLEAL BRAKE"
• The exposure of the intestinal lumen to fatty acids elicits a powerful inhibition of gastric motility. This phenomenon has been termed the "ileal brake" and its mechanism has been under investigation since the 1920's. Kosaka and Lim (54, 55) established that this ileal brake mechanism was, at least in part, hormonal, and that putative hormonal mediators isolated from the intestine possessed significant gastro-in-hibitory properties. This general class of inhibitory mediators were termed "enterogastrones". Considerable evidence has been collected in support of PYY as the principal mediator of this ileal brake effect (4, 5, 17, 26, 27) . It is released by ileal endocrine cells in response to luminal fatty acid stimulation (5, 6) . When administered into the circulation, PYY evokes a strong, vagally mediated inhibition of proximal digestive functions (5, 56) .
A dense concentration of PYY binding sites is located in the DVC; the site of vago-vagal reflex control circuitry responsible for the vagal modulation of proximal digestive tract functions. Recent investigations have revealed that the DVC does not have a significant vascular diffusion barrier (24) (25) (26) . Thus, peptides of the PP family have no difficulty gaining access to the extracellular spaces of the DVC.
Our studies with low doses of PYY applied directly to the DVC support the concept that the "enterogastrone" effects of PYY are mediated through the vagal innervation of the stomach. That is, (0 over a dose range consistent with physiological levels (4, 17, 27) , PYY produces a profound inhibition of vagally mediated gastric motility, (zz) gastroinhibitory effects of DVC PYY are duplicated by the Y2 agonist, and (in) neurophysiological studies (27) suggest that the PYY and Y2 agonist-evoked vagal gastroinhibition may be produced by direct inhibition of gastric DMN neurons.
CENTRAL VAGAL GASTROEXCITATORY ACTIONS OF PYY AND NPY; ACTION AT THE Y1 RECEPTOR.
• In spite of the strong evidence that PYY or its Y2 receptor analog are associated with a vagally mediated inhibition of gastric function, other evidence provided support for PYY and NPY as potential activators of gastric motility, also through a central vagal efferent mechanism (27, 28) . In these studies, higher doses of PYY delivered to the DVC evoked a significant stimulation of gastric motility. Geoghegan et al (29) and Lee et al (30) showed that ventricular injections of relatively high doses of NPY yielded significant increases in
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Biomed Rev 8, 1997 Peptide YY, neuropeptide Y, and control of digestion gastric motility, acid secretion and pancreatic secretion, all of which were vagally mediated. These investigators proposed that NPY was acting as part of a mechanism, which connects the onset of feeding behavior with the onset of the "cephalic phase" of digestion control.
Considerable experimental evidence links NPY with the central control of feeding behaviour. NPY microinjected into the paraventricular nucleus of the hypothalamus, or other nearby diencephalic regions which participate in the control of feeding behaviour, strongly elicits eating. NPY is synthesized in hypothalamic nuclei and released under conditions known to increase feeding behaviour, i.e. growth, pregnancy, and starvation (12) . Blockade of synthesis of NPY or its receptors reduces feeding behaviour (15, 57, 58) . Furthermore, there are significant NPYergic inputs to the DVC region of the brainstem (11, 43) . Given that NPY is strongly associated with the initiation of feeding behaviour, it seems reasonable to also expect descending NPYergic co-control of autonomic functions which augment digestion. However, in spite of the ideological arguments and experimental data in support of this mechanism (29, 30) , there are a number of reports which suggest that the central application of NPY, like PYY, could also produce a reduction in gastric motility or secretion (33) (34) (35) .
Y1 AND Y2 RECEPTORS IN THE DVC: RECIPROCAL CONTROL OF GASTRIC FUNCTION?
• One possible explanation for the conflicting nature of the effects of these peptides on gastric function involves the action of NPY and PYY on Y1 versus Y2 receptors in the DVC (27, 48, 49, 53) . Perhaps these two receptor populations (Yl and Y2) are normally segregated by morphological and/or physiological mechanisms which break down under experimental circumstances. For example, much of the PYY released from the ileum is rapidly converted to a specific Y2 agonist (PYY 3-36) by aubiquitous diaminopeptidase (DAP-IV) (57) . Under physiological conditions, PYY released into the circulation would ordinarily not exist long as a combined Y1-Y2 agonist, i.e. native PYY, thus eliminating any PYY crosstalk with Y1 and Y2 receptors. DAP-IV post-processing of peptide hormones and neurotransmitters within the central nervous system is now recognized as an important step in determining (Fig. 10) .
CONFOUNDS OF EXPERIMENTAL PEPTIDE APPLICATION
• The conflicting experimental results obtained by different doses and routes of central administration of PYY and NPY may be explained by simultaneous peptide actions at Y1 and Y2 sites which, under normal physiological conditions, may never occur (7). For example, CNS injection of a large amount of PYY may saturate DAP-IV, thereby allowing a significant amount of native PYY to gain access to Yl recep tors. Further, since PYY is being injected directly onto DVC structures (as opposed to arrival through the circulation), the peptide may be artificially placed in regions at high concen trations where it is not normally found, i.e. in the vicinity of Yl receptors. Since PYY has a very similar affinity for Y1 and Y2 receptors (13) , under experimental conditions, the peptide may activate both receptors, leading to conflicting results. Proof of this speculative scheme requires the histoanatomical demonstration that Y1 and Y2 receptors are located on different components of the DVC. Neurophysiological studies of Yl and Y2 agonist action on identifiable components of DVC motility regulation circuits will also be required to establish the functional significance of any difference in Yl and Y2 receptor distribution. Similar logic applies to the interpretation of central actions of NPY. Perhaps NPY is released primarily onto Y1 receptors as a neurotransmitter in the DVC. These Y1 receptors may be located outside the region where PYY might gain access via the circulation. Under normal circumstances, NPY would activate digestive functions via action on vagal mechanisms. Under experimental conditions, however, microinjection of NPY into the DVC would place it in contact withboth Yl and Y2 receptors. As with PYY, NPY has a nearly equivalent affinity for both YlandY2 receptors. Thus, the results of an application of NPY to the DVC by microinjection could be dependent upon the prevailing experimental conditions, e.g. basal versus stimulated motility. Critical histoanatomical and neurophysiological studies will be required to support or refute this hypothetical model .
CONCLUSION
• The vagal gastroinhibitory effects of PYY and NPY may be mediated by the Y2 receptor while the gastroexcita-tory effects of these same peptides may be mediated by the Yl receptor. The ultimate effects of Y2 and Yl receptor activation are inhibition and excitation, respectively, of DMN neurons which are responsible for controlling the cholinergic excitation of gastric smooth muscle. These observations may help to resolve some of the conflicting results obtained with these peptides in studies of autonomic control of digestive function.
